J&J buys Aragon’s prostate cancer arm


Hormonally-driven cancer drug discovery specialist Aragon Pharmaceuticals has been bought by Johnson & Johnson. The deal covers Aragon’s androgen receptor antagonist programme, including an advanced drug candidate for prostate cancer.

Androgen has spun out the rest of the company to form Seragon Pharmaceuticals, which will develop breast cancer drugs that work by degrading oestrogen receptors.

J&J paid $650 million (£417 million) up front, and will pay up to $350 million more if various milestones are reached. The androgen receptor antagonist programme will be managed by J&J’s subsidiary Janssen.


Related Content

Genentech to buy breast cancer specialist Seragon

2 July 2014 Business

news image

$1.7bn deal for hormone receptor-destroying drug pipeline

Business roundup

30 June 2011 Business

news image

Industry news, July 2011

Most Read

Perovskite solar cells show hydrogen production promise

26 September 2014 Research

news image

Highly efficient solar cells and catalysts made from cheap, common materials use sunlight to split water

Big name coffee chains drawn into acrylamide fight

23 September 2014 News and Analysis

news image

Starbucks and other coffee chains are being sued in California by a non-profit that wants carcinogen labels slapped on their ...

Most Commented

Perovskite solar cells show hydrogen production promise

26 September 2014 Research

news image

Highly efficient solar cells and catalysts made from cheap, common materials use sunlight to split water

First interstellar sighting of a branched alkyl molecule

25 September 2014 Research

news image

Discovery shows that stellar nurseries could hold amino acids too that might have been the spark for life on Earth